Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) EBITDA (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed EBITDA for 7 consecutive years, with -$23.6 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 52.99% to -$23.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$149.7 million through Dec 2025, up 28.83% year-over-year, with the annual reading at -$149.7 million for FY2025, 28.83% up from the prior year.
  • EBITDA for Q4 2025 was -$23.6 million at Pliant Therapeutics, up from -$26.3 million in the prior quarter.
  • The five-year high for EBITDA was -$22.8 million in Q1 2021, with the low at -$56.3 million in Q1 2025.
  • Average EBITDA over 5 years is -$37.1 million, with a median of -$35.7 million recorded in 2022.
  • The sharpest move saw EBITDA tumbled 305.99% in 2021, then skyrocketed 53.34% in 2025.
  • Over 5 years, EBITDA stood at -$24.7 million in 2021, then tumbled by 39.98% to -$34.6 million in 2022, then dropped by 12.42% to -$38.9 million in 2023, then fell by 29.34% to -$50.3 million in 2024, then skyrocketed by 52.99% to -$23.6 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$23.6 million, -$26.3 million, and -$43.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.